Brisbane, Australia – ImpediMed (ASX: IPD) is pleased to announce that the first joint American Cancer Society (ACS)/American Society of Clinical Oncology (ASCO) Breast Cancer Survivorship Care Guideline has now been published in the Journal of Clinical Oncology. The guideline recommends clinicians to focus on the early identification and management of lymphoedema and counsel survivors on how to prevent/reduce the risk of lymphoedema.
The clinical practice guideline addresses recommendations in 5 key areas of breast cancer survivorship, with lymphedema included under the assessment and management of physical and psychosocial long-term and late effects of breast cancer and treatment.
ImpediMed’s Managing Director and CEO Richard Carreon stated, “Inclusion of lymphoedema in the ACS/ASCO Breast Cancer Survivorship Care Guideline demonstrates the importance of counselling breast cancer survivors on the risk of lymphoedema. The growing focus on early identification and management of lymphoedema among patients with breast cancer is key in improving patient care and outcomes.”
Richard Carreon Managing Director & CEO
For further information contact:
Richard Carreon, ImpediMed Managing Director & CEO Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100
Kyahn Williamson, Buchan Investor and Media Relations T: +61 3 9866 4722
ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.